tremelimumab,savolitinib,durvalumab
hutchmed,pfizer,astrazeneca,orpathys
['savolitinib', 'calypso', 'tremelimumab', 'renal,(-adrenal)', 'durvalumab']
prof thomas powles ( ) from will be sharing the latest from calypso, a phase ii study of treatment regimens with durvalumab or savolitinib or tremelimumab in advanced clear cell renal cancer in a presentation at 20:45bst #asco22 
We're here to support our broad cancer research community of 4,000 scientists and clinicians. For general Cancer Research UK news & fundraising follow @CR_UK